Terns Pharmaceuticals Files 8-K on Shareholder Vote
Ticker: TERN · Form: 8-K · Filed: Jun 12, 2024 · CIK: 1831363
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, filing
TL;DR
Terns Pharma held a shareholder vote on June 10th, filing the details today.
AI Summary
Terns Pharmaceuticals, Inc. filed an 8-K on June 12, 2024, reporting on matters submitted to a vote of security holders on June 10, 2024. The filing details the company's principal executive offices located at 1065 East Hillsdale Blvd., Suite 100, Foster City, California.
Why It Matters
This filing indicates that Terns Pharmaceuticals held a shareholder vote, which could have implications for corporate governance and future strategic decisions.
Risk Assessment
Risk Level: low — This is a routine filing regarding a shareholder vote and does not appear to contain significant new financial or operational risks.
Key Players & Entities
- Terns Pharmaceuticals, Inc. (company) — Registrant
- June 10, 2024 (date) — Date of earliest event reported
- June 12, 2024 (date) — Date of report
- 1065 East Hillsdale Blvd., Suite 100, Foster City, California (location) — Principal Executive Offices
FAQ
What was the specific purpose of the shareholder vote on June 10, 2024?
The filing states it is a 'Submission of Matters to a Vote of Security Holders' but does not specify the exact proposals voted upon.
When was the 8-K filing officially submitted?
The 8-K filing was submitted on June 12, 2024.
Where are Terns Pharmaceuticals' principal executive offices located?
The principal executive offices are located at 1065 East Hillsdale Blvd., Suite 100, Foster City, California.
What is the Commission File Number for Terns Pharmaceuticals?
The Commission File Number is 001-39926.
What is the Standard Industrial Classification for Terns Pharmaceuticals?
The Standard Industrial Classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 598 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-06-12 16:15:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TERN Nasdaq Glo
Filing Documents
- tern-20240610.htm (8-K) — 47KB
- 0000950170-24-072462.txt ( ) — 166KB
- tern-20240610.xsd (EX-101.SCH) — 26KB
- tern-20240610_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 10, 2024, Terns Pharmaceuticals, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on two proposals, each of which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 25, 2024. Only stockholders of record as of the close of business on April 18, 2024, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 64,674,780 shares of the Company's common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows: Proposal 1 . The election of two Class III directors to hold office until the 2027 annual meeting of stockholders or until their respective successor is elected: Nominee Votes For Votes Withheld Broker Non-Votes Jeffrey Kindler 45,958,352 6,735,358 5,131,121 Amy Burroughs 52,570,019 123,691 5,131,121 Proposal 2 . The ratification of the selection, by the audit committee of the board of directors, of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024: Votes For Votes Against Abstentions 57,570,954 23,950 229,927 As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TERNS PHARMACEUTICALS, INC. Date: June 12, 2024 By: /s/ Bryan Yoon Bryan Yoon Chief Operating Officer & General Counsel